{"id":"ibrutinib-induction","safety":{"commonSideEffects":[{"rate":"50-60","effect":"Diarrhea"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Nausea"},{"rate":"20-30","effect":"Bruising/bleeding"},{"rate":"25-35","effect":"Infection"},{"rate":"5-10","effect":"Atrial fibrillation"},{"rate":"15-25","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ibrutinib covalently binds to BTK, a key enzyme in the B-cell receptor signaling pathway. By inhibiting BTK, it disrupts downstream signaling cascades that promote B-cell survival and proliferation, making it particularly effective against B-cell malignancies. In the induction phase, it is used as an initial treatment to rapidly reduce tumor burden before consolidation or maintenance therapy.","oneSentence":"Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, leading to reduced proliferation and survival of malignant B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:24.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL), induction phase"},{"name":"Mantle cell lymphoma, induction phase"},{"name":"Waldenström macroglobulinemia, induction phase"}]},"trialDetails":[{"nctId":"NCT03697512","phase":"PHASE2","title":"MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2019-09-27","conditions":"Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma","enrollment":175},{"nctId":"NCT03731234","phase":"PHASE2","title":"Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2019-07-02","conditions":"DLBCL","enrollment":75},{"nctId":"NCT05672173","phase":"PHASE2","title":"Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-06-02","conditions":"Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome","enrollment":20},{"nctId":"NCT03620903","phase":"PHASE2","title":"Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Christian Buske","startDate":"2019-09-11","conditions":"Waldenstrom Macroglobulinemia","enrollment":53},{"nctId":"NCT04446962","phase":"PHASE1, PHASE2","title":"LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2020-10-30","conditions":"Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary","enrollment":118},{"nctId":"NCT04848493","phase":"","title":"National Project on Vaccines, COVID-19 and Frail Patients","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2021-04-19","conditions":"COVID-19, Solid Tumor, Hematologic Diseases","enrollment":747},{"nctId":"NCT02388048","phase":"PHASE2","title":"Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2015-10","conditions":"Leukemia, Lymphoblastic, Chronic","enrollment":19},{"nctId":"NCT02692248","phase":"PHASE2","title":"Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2016-04-07","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":64},{"nctId":"NCT06482684","phase":"PHASE2","title":"CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma","status":"RECRUITING","sponsor":"Christian Schmidt, MD","startDate":"2024-02-15","conditions":"Mantle Cell Lymphoma","enrollment":150},{"nctId":"NCT02997761","phase":"PHASE2","title":"Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Brian Jonas","startDate":"2017-06-27","conditions":"Adult B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive","enrollment":20},{"nctId":"NCT02451111","phase":"PHASE2","title":"Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2015-11-06","conditions":"Follicular Lymphoma","enrollment":190},{"nctId":"NCT02242097","phase":"PHASE2","title":"Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2015-01-12","conditions":"Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma","enrollment":37},{"nctId":"NCT04375397","phase":"PHASE2","title":"Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-06-06","conditions":"CoronaVirus Induced Disease-2019 (COVID-19)","enrollment":46},{"nctId":"NCT04639362","phase":"PHASE2","title":"CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2020-12-29","conditions":"CLL","enrollment":85},{"nctId":"NCT04994626","phase":"PHASE2","title":"Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-10-01","conditions":"DLBCL, MYD88 Gene Mutation, CD79A Gene Mutation","enrollment":20},{"nctId":"NCT04992377","phase":"PHASE2","title":"R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-08-30","conditions":"Richter Transformation","enrollment":30},{"nctId":"NCT02689869","phase":"PHASE2","title":"Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2016-04","conditions":"Indolent Non-Hodgkin Lymphoma","enrollment":98},{"nctId":"NCT03755947","phase":"PHASE2","title":"Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Grupo Cooperativo de Hemopatías Malignas","startDate":"2018-12-01","conditions":"B-Cell Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)","enrollment":3},{"nctId":"NCT02689141","phase":"PHASE2","title":"Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2016-02-04","conditions":"Chronic Lymphocytic Leukemia","enrollment":66},{"nctId":"NCT04066920","phase":"PHASE2","title":"IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL","status":"UNKNOWN","sponsor":"Deok-Hwan Yang","startDate":"2019-10-01","conditions":"Primary Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT03980002","phase":"PHASE2","title":"A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2019-05-15","conditions":"Chronic Lymphocytic Leukemia","enrollment":50},{"nctId":"NCT02345863","phase":"PHASE2","title":"Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2015-01-16","conditions":"Chronic Lymphocytic Leucemia","enrollment":66},{"nctId":"NCT02635074","phase":"PHASE1","title":"Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Steven E. Coutre","startDate":"2016-11","conditions":"Recurrent Adult Acute Myeloid Leukemia","enrollment":2},{"nctId":"NCT02858258","phase":"PHASE3","title":"ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Prof. Dr. M. Dreyling (co-chairman)","startDate":"2016-07","conditions":"Mantle Cell Lymphoma","enrollment":870}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":180,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Imbruvica"],"phase":"phase_3","status":"active","brandName":"Ibrutinib (Induction)","genericName":"Ibrutinib (Induction)","companyName":"Prof. Dr. M. Dreyling (co-chairman)","companyId":"prof-dr-m-dreyling-co-chairman","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, leading to reduced proliferation and survival of malignant B cells. Used for Chronic lymphocytic leukemia (CLL), induction phase, Mantle cell lymphoma, induction phase, Waldenström macroglobulinemia, induction phase.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}